SCHEMBL4667481

SCHEMBL4667481

CN1CCC(COc2ccc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccc(F)cc5F)cc4)ncn3)cc2F)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 2/20 0.42
PIK3CA P42336 2/20 0.42
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
KDR P35968 4/20 0.38
MET P08581 2/20 0.38
EGFR P00533 6/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664427 0.95 PIK3R1 (0.44) PIK3R1PIK3CAMEN1USP2ALDH1A1
SCHEMBL4665630 0.94 PIK3R1 (0.45) PIK3R1PIK3CAMEN1USP2ALDH1A1
SCHEMBL4663781 0.94 EGFR (0.39) PIK3R1PIK3CAMEN1USP2ALDH1A1
SCHEMBL4665896 0.93 MEN1 (0.38) PIK3R1PIK3CAMEN1USP2ALDH1A1
SCHEMBL4665829 0.93 EGFR (0.39) MEN1USP2ALDH1A1TP53CYP1A2
SCHEMBL4665770 0.92 MEN1 (0.42) PIK3R1PIK3CAMEN1USP2ALDH1A1
SCHEMBL4667543 0.90 EGFR (0.39) MEN1USP2ALDH1A1TP53CYP1A2
SCHEMBL4665748 0.89 EGFR (0.42) KDRMETEGFRKITIKBKE
SCHEMBL4663828 0.88 EGFR (0.44) PIK3R1PIK3CAKDRMETEGFR
SCHEMBL4665787 0.88 ABL1 (0.41) KDRMETEGFRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 PIK3R1 385/4885PIK3CA 161/4885MEN1 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.